Gufic Biosciences reported a strong start to FY27, with standalone net profit rising 23% year-on-year to ₹799.3 million for the quarter ended June 30, 2026. The growth was underpinned by a 15% increase in total income from operations, which logged ₹1,172.6 million, compared to ₹1,018.7 million in the corresponding period of the previous year.

On a consolidated basis, the company’s net profit after tax stood at ₹960.2 million, up from ₹781.4 million in Q1FY26. Consolidated revenue from operations grew 14% to ₹1,408.3 million, reflecting broad-based operational improvement across its business segments. The board of directors approved the unaudited financial results in a meeting held on August 14, 2026.

Financial Performance

The company’s profitability metrics showed consistent expansion both standalone and on a consolidated basis. Standalone profit before tax increased to ₹883.7 million from ₹717.8 million last year. On a consolidated level, profit before tax rose to ₹1,203.3 million from ₹983.9 million.

Earnings per share (basic) for the standalone entity were reported at ₹23.56, compared to ₹19.06 in the same quarter last year. Consolidated basic EPS stood at ₹35.78, an increase from ₹29.06 previously.

What the Numbers Show

The divergence between standalone and consolidated earnings highlights the significant contribution of subsidiaries to the group’s bottom line. While standalone revenue constituted approximately 83% of consolidated revenue, the standalone net profit accounted for only about 83% of the consolidated net profit, indicating efficient leverage or higher margins within certain consolidated entities. Furthermore, the consistent 23% growth rate in net profit across both standalone and consolidated structures suggests that the top-line revenue growth is translating directly into improved profitability without disproportionate cost inflation.

Regulatory Compliance

The financial results have been reviewed by the Audit Committee and approved by the Board of Directors. The statutory auditors have carried out a limited review of the results and expressed an unmodified audit opinion. The detailed format of the quarterly results is available on the websites of the stock exchanges and the company.

Gufic Biosciences has scheduled its 42nd Annual General Meeting (AGM) for Friday, September 4, 2026, at 3:30 pm. The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM), in compliance with Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) circulars permitting virtual meetings without physical presence.

Key Agenda Items

The primary business to be transacted includes the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The Board has recommended a final dividend of ₹0.10 per equity share of face value ₹1 each for FY26. This payout is subject to approval by shareholders at the AGM.

Additionally, the meeting will address special business resolutions regarding board appointments and auditor remuneration:

• Re-appointment of Whole Time Director: Shareholders will vote on the re-appointment of Mr. Pankaj J. Gandhi (DIN: 00001858) as Whole Time Director for a further term of five years, commencing September 7, 2026, and ending September 6, 2031. The resolution also seeks approval for his continuation in office beyond the age of 70 years, which he will attain during this tenure. His annual salary is capped at ₹1 crore, inclusive of increments, along with standard perquisites and allowances.
• Cost Auditor Remuneration: The Board proposes ratifying the remuneration of M/s. Poddar & Co. (FRN: 101734) as Cost Auditors for FY27. The approved fee is ₹4 lakh per annum plus applicable taxes and reimbursement of actual out-of-pocket expenses.
• Director Retirement by Rotation: Mr. Pranav J. Choksi (DIN: 00001731), son of Chairman & Managing Director Mr. Jayesh P. Choksi, retires by rotation and offers himself for re-appointment.

Book Closure and Record Date

The Register of Members and Share Transfer Books will remain closed from Saturday, August 29, 2026, to Friday, September 4, 2026, both days inclusive. This closure facilitates the determination of shareholders eligible for the AGM and the payment of the final dividend for FY26.

Voting and Participation

The company is providing remote e-voting facilities through National Securities Depository Limited (NSDL). The remote e-voting period commences on Tuesday, September 1, 2026, at 9:00 am and ends on Thursday, September 3, 2026, at 5:00 pm. Only members holding shares as on the record date are eligible to vote. The facility for appointing proxies has been dispensed with due to the virtual nature of the meeting.

What the Numbers Show

The proposed final dividend of ₹0.10 per share represents a 10% payout on the ₹1 face value. While the filing does not disclose total equity capital or prior-year dividend comparisons within this notice, the consistent recommendation of dividends indicates ongoing cash generation capability. The re-appointment of Mr. Gandhi, who holds no shares in the company, aligns executive retention with regulatory compliance rather than equity-based incentives.